<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): MARCH 8, 1999
GENEMEDICINE, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-24572 76-0355802
(Commission File No.) (IRS Employer Identification No.)
8301 NEW TRAILS DRIVE
THE WOODLANDS, TEXAS 77381-4248
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (281) 364-1150
<PAGE>
ITEM 5. OTHER EVENTS.
On March 8, 1999, Onyx Pharmaceuticals Inc. ("Onyx") announced that Norman
Hardman, Ph.D., the current President and Chief Operating Officer of
GeneMedicine, inc. (the "Company"), will join Onyx as its Chief Operating
Officer following the completion of the merger between the Company and Montana
Acquisition Sub, Inc., a wholly-owned subsidiary of Megabios Corp (the
"Merger").
Josef Bossart, Vice President and Chief Business Officer of the Company,
has announced his intention to join Enzon, Inc. ("Enzon") as President -- SCA
Ventures following the completion of the Merger.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEMEDICINE, INC.
Dated: March 9, 1999 By: /s/ Richard A. Waldron
----------------------------
Richard A. Waldron
Chief Financial Officer
